Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

Completed · Not applicable

Conditions studied: Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration

In brief

The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD. The effects of Lumega-Z supplementation will be compared to an active comparator, the AREDS2 multivitamin.

Key facts

Study ID

NCT03946085

Run by

Guardion Health Sciences, Inc.

People needed

79

Starts

2018-01-19

Expected to finish

2018-11-01

Last updated by the study team

2019-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• patients with retinal drusen (as determined by clinical fundus photography examination) and dark adaptation recovery time of 6 to 10 minutes.

You may not qualify if…

• presence of congenital retinal pathologies that may impact data collection
• prior history of retinal-detachment or vitreo-retinal surgeries with any complications
• best-corrected visual acuity of 20/40 or worse

Where it is running

• Eye Clinic of Austin — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.